Irinotecan Sun (Irinotecan Hydrochloride Trihydrate)

After infusion, Irinotecan is metabolized to SN‑38, which binds to the DNA‑topoisomerase I complex. This binding prevents the enzyme from resealing DNA strands during replication, causing DNA breaks that trigger apoptosis in rapidly dividing cancer cells.

The dosing regimen for Irinotecan Sun is individualized by the treating physician based on factors such as cancer type, patient weight, performance status, and laboratory values. Only a qualified prescriber can determine the appropriate dose and schedule.

Safety data for Irinotecan in pregnancy and lactation are limited. It is generally contraindicated during pregnancy because of potential fetal harm, and breastfeeding is not recommended while receiving treatment, as the drug may be excreted in milk.

To place an order, submit an enquiry on the Irinotecan Sun product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, offering a different mechanism from fluoropyrimidines or oxaliplatin. It is often used in combination regimens (e.g., FOLFIRI) and provides benefit in patients who have progressed on other agents, though its toxicity profile, especially diarrhea and neutropenia, requires careful monitoring.

Irinotecan Sun should be stored at 2‑8 °C in a refrigerator, protected from light, and never frozen. Vials must be kept in their original packaging until use, and any prepared infusion should be administered promptly according to aseptic technique.

Irinotecan Sun is given as an intravenous infusion, typically over 30 to 90 minutes depending on the protocol. The infusion is performed in a clinical setting by qualified healthcare professionals, with pre‑medication and monitoring for infusion‑related reactions as required.

The most serious adverse events include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea that can lead to dehydration or colitis, and rare but critical allergic reactions. Prompt recognition and supportive care are essential to mitigate these risks.

Irinotecan Sun is contraindicated in patients with known hypersensitivity to Irinotecan or its excipients, those with active severe infections, uncontrolled bowel obstruction, or significant hepatic impairment. Caution is also advised for patients with deficient UGT1A1 activity, as they may experience heightened toxicity.